Gene therapy of inherited and acquired hearing loss

Project Information

iHEAR

Grant agreement ID: 819531

DOI 10.3030/819531

EC signature date 12 February 2019

Start date 1 May 2019

End date 31 October 2024

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost € 1 999 500,00

EU contribution € 1 999 500,00

Coordinated by

MEDIZINISCHE HOCHSCHULE HANNOVER
Germany

Publications

Peer reviewed articles (8)

Gene therapy as a possible option to treat hereditary hearing loss

Author(s): Michael Morgan, Juliane W. Schott, Axel Rossi, Christian Landgraf, Athanasia Warnecke, Hinrich Staecker, Anke Lesinski-Schiedat, Brigitte Schlegelberger, Hildegard Büning, Bernd Auber, Axel Schambach
Published in: Medizinische Genetik, Issue Volume 32: Issue 2, 2020, ISSN 1863-5490
Publisher: De Gruyter
DOI: 10.1515/medgen-2020-2021

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells

Author(s): Michael Morgan, Hildegard Büning, Martin Sauer, Axel Schambach
Published in: Frontiers in Immunology, Issue 11, 2020, Page(s) 1965, ISSN 1664-3224
Publisher: Frontiers Media
DOI: 10.3389/fimmu.2020.01965

Competitive sgRNA Screen Identifies p38 MAPK as a Druggable Target to Improve HSPC Engraftment

Author(s): Denise Klatt, Teng-Cheong Ha, Maximilian Schinke, Anton Selich, Anna Lieske, Julia Dahlke, Michael Morgan, Tobias Maetzig, Axel Schambach
Published in: Cells, Issue 9/10, 2020, Page(s) 2194, ISSN 2073-4409
Publisher: MDPI
DOI: 10.3390/cells9102194

Genetic Correction of IL-10RB Deficiency Reconstitutes Anti-Inflammatory Regulation in iPSC-Derived Macrophages

Author(s): Dirk Hoffmann, Johanna Sens, Sebastian Brennig, Daniel Brand, Friederike Philipp, Philippe Vollmer Barbosa, Johannes Kuehle, Doris Steinemann, Daniela Lenz, Theresa Buchegger, Michael Morgan, Christine S Falk, Christoph Klein, Nico Lachmann, Axel Schambach
Published in: Journal of Personalized Medicine, Issue 11(3), 2021, Page(s) 221, ISSN 2075-4426
Publisher: MDPI
DOI: 10.3390/jpm11030221

Retroviral gene therapy in Germany with a view on previous experience and future perspectives

Author(s): Michael A Morgan, Melanie Galla, Manuel Grez, Boris Fehse, Axel Schambach
Published in: Gene Therapy, Issue 28(9), 2021, Page(s) 494-512, ISSN 1476-5462
Publisher: Nature Publishing Group
DOI: 10.1038/s41434-021-00237-x

Inducible Forward Programming of Human Pluripotent Stem Cells to Hemato-endothelial Progenitor Cells with Hematopoietic Progenitor Potential

Author(s): Lucas Lange, Dirk Hoffmann, Adrian Schwarzer, Teng-Cheong Ha, Friederike Philipp, Daniela Lenz, Michael Morgan, Axel Schambach
Published in: Stem Cell Reports, Issue 14/1, 2020, Page(s) 122-137, ISSN 2213-6711
Publisher: Cell Press
DOI: 10.1016/j.stemcr.2019.11.005

Challenges and advances in translating gene therapy for hearing disorders

Author(s): Hildegard Büning, Axel Schambach, Michael Morgan, Axel Rossi, Helena Wichova, Hinrich Staecker, Athanasia Warnecke, Thomas Lenarz
Published in: Expert Review of Precision Medicine and Drug Development, Issue 5/1, 2020, Page(s) 23-34, ISSN 2380-8993
Publisher: Taylor and Francis Online
DOI: 10.1080/23808993.2020.1707077

Third-generation lentiviral gene therapy rescues function in a mouse model of Usher 1B

Author(s): Juliane W Schott, Peixin Huang, Michael Morgan, Jennifer Nelson-Brantley, Ally Koehler, Bryan Renslo, Hildegard Büning, Athanasia Warnecke, Axel Schambach, Hinrich Staecker
Published in: Molecular Therapy, 2023, ISSN 1525-0024
Publisher: Cell Press
DOI: 10.1016/j.ymthe.2023.10.018